On Wednesday, Marketo Inc (NASDAQ:MKTO)’s shares inclined 3.37% to $24.85.
Marketo, Inc. (MKTO), declared that Envera Systems, a virtual security provider for housing communities, has implemented Marketo’s Engagement Marketing Platform to better gauge its return on its investments in marketing, provide sales with higher quality leads, and better engage with its audience at-scale.
Envera Systems, which operates in more than 30 counties in Florida and serves hundreds of housing and condominium communities and associations throughout the state, needed to gain insight into their marketing programs and calculate ROI and analytics in a timely manner. Additionally, Envera’s marketing team needed to manage a high volume of events and quickly provide sales with leads.
Marketo, Inc. provides cloud-based marketing software platform that enables organizations to engage in relationship marketing in the United States. The company’s Engagement Marketing Platform enables the execution, administration, and analytical measurement of online, social, and offline marketing activities and customer interactions. It offers various applications, such as Marketing Automation, which provides a set of capabilities for marketers to create, automate, and track personalized multi-channel marketing campaigns and relationship-marketing workflows; Sales Insight that enables customers to view automated highlights, best leads, and opportunities; and Revenue Analytics, which provides various solutions for companies to understand the correlation between marketing programs and revenue outcomes.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s shares dropped -0.12% to $33.66.
Sarepta Therapeutics, Inc. (SRPT), a developer of innovative RNA-targeted therapeutics, recently declared the publication of results from a multiple ascending dose study to determine the safety of AVI-7288, a PMOplus® antisense oligonucleotide, in healthy adult volunteers, in the July 23, 2015 issue of The New England Journal of Medicine. The results of the study, conducted in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), demonstrated no clinical or toxicologic safety concerns with AVI-7288, an investigational treatment for Marburg Virus (MARV) infection. These results add to the continued documentation of safety data for Sarepta’s PMO-based technology.
AVI-7288 utilizes Sarepta’s advanced and proprietary PMOplus® technology. AVI-7288 is designed to bind to viral messenger RNA encoding Marburg Virus nucleoprotein to inhibit nucleoprotein synthesis and prevent viral replication and assembly. This mechanism of AVI-7288 is fundamentally distinct from other RNA-based anti-infective therapies that utilize a gene editing or degradation pathway. Additionally, this approach highlights the flexibility and precision of the PMO-based platform.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
At the end of Wednesday’s trade, Eagle Materials, Inc. (NYSE:EXP)‘s shares dipped -1.37% to $76.28.
Eagle Materials Inc. (EXP) will release financial results for the first quarter of fiscal 2016 ended June 30, 2015, on Monday, August 3, 2015, after the close of the NYSE and will host an investor conference call the next day, Tuesday, August 4, 2015, at 10:00 am Eastern Time (9:00 am Central Time).
Eagle Materials Inc. produces and sells construction products and building materials used in residential, industrial, commercial, and infrastructure construction; and products used in oil and natural gas extraction in the United States. The company operates in five segments: Cement, Gypsum Wallboard, Recycled Paperboard, Concrete and Aggregates, and Oil and Gas Proppants. The Cement segment is involved in the mining of limestone; and manufacture, production, distribution, and sale of portland cement, in addition to specialty oil well cement. The Gypsum Wallboard segment engages in the mining of gypsum; and manufacture and sale of gypsum wallboard used to finish the interior walls and ceilings in residential, commercial, and industrial structures.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
